www.jhoonline.org

Table 1
Indication and efficacy for selected agents in advanced RCC
Indications	Agent	Target	Efficacy

1^stline

Poor risk	Temsirolimus	mTOR	Survival benefit (HR: 0.73) [33]
Good risk and clear cell	High dose IL-2	Immunomodulation	ORR: 14% (potential durable response) [99,100]
Good and intermediate risk	Sunitinib	VEGFR 1,2,3, PDGFR α,β Abl, Src	Survival benefit (HR: 0.82) [22]
Good and intermediate risk	Bevacizumab/Interferon	VEGF/Immunomodulation	PFS benefit (HR: 0.63) [49]

2^ndline

Prior cytokine therapy	Sorafenib	VEGFR 1,2,3, PDGFR, C-kit, Flt-3, RET	PFS benefit (HR: 0.44) [12]
Prior TKIs	Everolimus	mTOR	PFS benefit (HR: 0.30) [35]

Clinical trials

	Thalidomide	Immunomodulation and angiogenesis	ORR: 0% [42]
	Lenalidomide	Immunomodulation and angiogenesis	ORR: 11% [44]
	Axitinib	VEGFR 1,2, PDGFR, C-kit	ORR: 21–44.2% [24,101]
	Pazopanib	VEGFR 1,2,3, PDGFR, C-kit	ORR: 34.7% [27]
	Cediranib	VEGFR 1,2,3, PDGFR, C-kit, FLT-4	ORR: 38% [29]
	G250	CA IX	ORR: 10% [57]
	Ixabepilone	Cytotoxic	ORR: 12.6% [58]

Abbreviations: RCC, renal cell cancer; mTOR, mammalian target of rapamycin; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet derived growth factor receptor; c-KIT, stem-cell growth factor receptor; Flt-3 and -4, Fms-like tyrosine kinases 3 and 4; HR, hazard ratio; ORR, objective response rate; PFS, progression-free survival.
Chu and Wu Journal of Hematology & Oncology 2008 1:11 doi:10.1186/1756-8722-1-11

Table 1